Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.82 |
| ▸ | PTK6 | Q13882 | 12/20 | 0.82 |
| ▸ | SRC | P12931 | 13/20 | 0.80 |
| ▸ | FYN | P06241 | 5/20 | 0.80 |
| ▸ | KDR | P35968 | 3/20 | 0.65 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.65 |
| ▸ | EGFR | P00533 | 2/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.65 |
| ▸ | PRKDC | P78527 | 2/20 | 0.65 |
| ▸ | BACE1 | P56817 | 1/20 | 0.65 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.65 |
| ▸ | HCK | P08631 | 7/20 | 0.65 |
| ▸ | BLK | P51451 | 5/20 | 0.65 |
| ▸ | LCK | P06239 | 5/20 | 0.65 |
| ▸ | LYN | P07948 | 4/20 | 0.65 |
| ▸ | YES1 | P07947 | 2/20 | 0.65 |
| ▸ | FGR | P09769 | 2/20 | 0.65 |
| ▸ | FRK | P42685 | 4/20 | 0.62 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25030550 | 1.00 | ABL1 (0.82) | ABL1PTK6SRCFYNKDR | |
| SCHEMBL30183417 | 0.92 | ABL1 (0.85) | ABL1PTK6SRCFYNKDR | |
| SCHEMBL25030590 | 0.92 | ABL1 (0.85) | ABL1PTK6SRCFYNKDR | |
| SCHEMBL18258351 | 0.90 | PTK6 (1.00) | ABL1PTK6SRCFYNKDR | |
| SCHEMBL20132566 | 0.90 | ABL1 (1.00) | ABL1PTK6SRCFYNKDR | |
| SCHEMBL18258365 | 0.89 | SRC (1.00) | ABL1PTK6SRCFYNKDR | |
| SCHEMBL29381545 | 0.89 | ABL1 (1.00) | ABL1PTK6SRCFYNKDR | |
| SCHEMBL18258375 | 0.89 | ABL1 (1.00) | ABL1PTK6SRCFYNKDR | |
| SCHEMBL26148156 | 0.89 | ABL1 (0.92) | ABL1PTK6SRCFYNKDR | |
| SCHEMBL18258331 | 0.88 | ABL1 (1.00) | ABL1PTK6SRCFYNKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384518-B1 | TYROSINE KINASE INHIBITORS | UNIV COURT UNIV OF EDINBURGH (GB) | 2025-12-17 | — | — | EP | disclosed |
| US-20250092046-A1 | TYROSINE KINASE INHIBITORS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2025-03-20 | — | — | US | disclosed |
| CN-117957229-A | Tyrosine kinase inhibitors | 爱丁堡大学理事会 | 2024-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092046-A1 | TYROSINE KINASE INHIBITORS | ABL1, ALK, TYRO3 | ABL1 1/4885PTK6 111/4885SRC 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.